Melanoma Clinical Trials in Baltimore

Showing 141-160 of 177 trials

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

NCT00441337

To evaluate the safety, tolerability, efficacy, and pharmacokinetics of MDX-1106 when administered to patients with advanced non-small cell lung cancer, colorectal cancer, malignant melanoma, clear cell renal cell cancer or hormone refractory prostate cancer

Carcinoma, Non-Small-Cell LungColorectal CancerMalignant Melanoma+2 more

Bristol-Myers Squibb39 participantsStarted Aug 2006

Baltimore, Maryland, United States • Detroit, Michigan, United States • St Louis, Missouri, United States +1 more locations

COMPLETEDPHASE134 miles

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

NCT00005057

RATIONALE: Inserting a modified herpesvirus gene into a person's melanoma cells may make the cancer more sensitive to the antiviral agent ganciclovir. PURPOSE: Phase I trial to study the effectiveness of gene therapy in treating patients who have stage IV melanoma.

Melanoma (Skin)

National Human Genome Research Institute (NHGRI)Started Mar 2000

Bethesda, Maryland, United States • Bethesda, Maryland, United States • Houston, Texas, United States

COMPLETEDPHASE234 miles

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

NCT00019669

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. It is not yet known whether combining melanoma vaccine with interleukin-2 is more effective than vaccine therapy alone in treating metastatic melanoma. PURPOSE: Phase II trial to compare the effectiveness of melanoma vaccine and interleukin-2 with that of melanoma vaccine alone in treating patients who have metastatic melanoma that has not responded to previous treatment.

Melanoma (Skin)

National Cancer Institute (NCI)Started Oct 1999

Bethesda, Maryland, United States

A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies

Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Melanoma Trials in Other Cities

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma

Isotretinoin in Preventing Skin Cancer

Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

CCI-779 in Treating Patients With Metastatic Melanoma

Vaccine Therapy in Treating Patients With Malignant Melanoma

A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma

Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases

MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.

Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma

Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

SciBase International Melanoma Pivotal Study

Other Conditions in Baltimore